Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subendometrial vs Intrauterine PRP for Recurrent Implantation Failure
NCT07306871Active, not recruiting
- Sponsor
- Minia University
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Randomised, open-label trial of autologous platelet-rich plasma in Recurrent Implantation Failure (RIF) (3 arms), sponsored by Minia University. Primary endpoint: Implantation rate at 5 weeks. Started Jan 2026; status: active, not recruiting.
02
Drugs
autologous platelet-rich plasma
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT07306871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306871.